论文部分内容阅读
7月15日《人民日报》报道,近年来,GSK中国为达到打开药品销售渠道、提高药品售价等目的,利用旅行社等渠道,采取直接行贿或赞助项目等方式,向政府部门个别官员、医药行业协会和基金会、医院、医生等大肆行贿。据报道,GSK在华唯一的收入来源就是药品销售,这意味着巨额的“黑金”都将被转嫁到药价中,最终由患者埋单。成本仅30元的药,最终卖到患者手里能达到300元,“这个运营费用在药价中占的比重有20%—30%”。公安部有关部门负责人表示,GSK一案仅暴露了整个行业的冰山一角。
In July 15th, “People’s Daily” reported that in recent years, GSK China has adopted various channels such as travel agents and direct bribery or sponsorship projects to open up drug sales channels and raise drug prices. Industry associations and foundations, hospitals, doctors and other wanton bribery. It is reported that GSK’s only source of income in China is drug sales, which means that a huge amount of “black gold” will be passed on to drug prices and will eventually be billed by the patients. The cost of only 30 yuan of medicine, the final sold to the patient’s hand can reach 300 yuan, “This operating costs in drug prices accounted for 20% -30%.” Ministry of Public Security officials said the GSK case exposed only the tip of the iceberg of the entire industry.